* 1, 2
*
SPIRIVA ® Respimat ®( tiotropium) significantly delays time to first severe exacerbation of asthma vs placebo, when added to ICS / LABA, p < 0.05
SPIRIVA ® Respimat ® in asthma:
Now available for symptomatic adult asthma patients as an add-on therapy to ICS / LABA † 1
†
ICS( ≥800 μg budesonide / day or equivalent) plus LABA, in patients who experienced ≥1 severe exacerbations in the past year.
ICS, inhaled corticosteroids; LABA, long-acting beta 2 agonist
PBS Information: Restricted benefit. Severe Asthma Code 11043F. Refer to PBS Schedule for full restricted benefit information.
Please review Product Information before prescribing. Full Product Information is available at www. boehringer-ingelheim. com. au / PI. Further information is available from Boehringer Ingelheim Pty Ltd.
SPIRIVA ® RESPIMAT ®( tiotropium bromide) solution for inhalation. INDICATIONS: COPD: Long term maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease( COPD). Prevention of COPD exacerbations. Asthma: Add-on maintenance bronchodilator treatment in adult patients with asthma, currently treated with the maintenance combination of inhaled corticosteroids( ≥800 µ g budesonide / day or equivalent) and long-acting ß 2 agonists and who experienced one or more severe exacerbations in the previous year. CONTRAINDICATIONS: Hypersensitivity to tiotropium bromide, atropine or its derivatives, or to any of the excipients. PRECAUTIONS: Should not be used for: treatment of acute episodes of bronchospasm, relief of acute symptoms, first-line treatment for asthma. Immediate hypersensitivity reactions, narrow-angle glaucoma, prostatic hyperplasia, bladder-neck obstruction, urinary retention, micturition difficulties, dry mouth, inhalation-induced bronchospasm, recent myocardial infarction(< 6 months), unstable or life-threatening cardiac arrhythmia within past year, hospitalisation for heart failure within past year, moderate to severe renal impairment( CrCL ≤50 mL / min), pregnancy, lactation, children. Avoid solution or mist entering eyes. INTERACTIONS: Co-administration with anticholinergic drugs. ADVERSE EFFECTS: Common: Dry mouth, usually mild. Others, see full PI. DOSAGE: For oral inhalation. 5 μg tiotropium given as two puffs once daily, at the same time each day. Do not exceed recommended dose. Cartridges to be used only with RESPIMAT inhaler. July 2015.
References: 1. SPIRIVA Respimat Approved Product Information, 13 September 2016. 2. Kerstjens HA, et al. N Engl J Med 2012; 367: 1198 – 1207. SPIRIVA ® and RESPIMAT ® are registered trademarks of Boehringer Ingelheim. Boehringer Ingelheim Pty Ltd. ABN 52 000 452 308. 78 Waterloo Road, North Ryde, NSW 2113. AUS / SPI-161245f. BISR12631W / AD / FP. July 2017.